SAB BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.1 USD | -4.43% |
|
-6.82% | -40.36% |
| 04-16 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
| 04-02 | HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.82M 3.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -45M -3.59B | Net income 2025 * | -57M -4.55B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.95
x | P/E ratio 2025 * |
-0.66
x | Employees | 57 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.39% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -4.43% | ||
| 1 week | -6.82% | ||
| Current month | -4.43% | ||
| 1 month | -4.43% | ||
| 3 months | -30.51% | ||
| 6 months | -59.00% | ||
| Current year | -40.36% |
1 week
4.10
4.39
1 month
4.014.94
Current year
4.007.00
1 year
4.0011.90
3 years
3.66129.00
5 years
3.66129.00
10 years
3.66129.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 21/10/21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 21/10/21 |
Michael King
DFI | Director of Finance/CFO | 63 | 29/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 21/10/21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 21/10/21 |
Erick Lucera
BRD | Director/Board Member | 57 | 02/04/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 4.1 | -4.43% | 336 |
| 30/04/24 | 4.29 | +2.39% | 805 |
| 29/04/24 | 4.19 | -1.41% | 2,681 |
| 26/04/24 | 4.25 | +5.98% | 4,877 |
| 25/04/24 | 4.01 | -8.86% | 794 |
Delayed Quote Nasdaq, May 01, 2024 at 09:30 pm
More quotes
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.1
USD
Average target price
15.5
USD
Spread / Average Target
+278.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.36% | 37.82M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +2.13% | 22.25B | |
| -14.77% | 21.68B | |
| -8.79% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- SABS Stock
